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Background
V198M mutation has been identified in more than one
CAPS phenotype and is difficult to treat.
Aim
To report effects of prolonged selective IL-1b inhibition
with canakinumab in a CAPS phenotype related to
V198M mutation.
Methods
A 9-year old boy, diagnosed with symptomatic MWS
and evidence of a V198M mutation (father also
V198M), only partially responsive to anakinra, partici-
pated in a phase III study of canakinumab in CAPS
patients (N=166). Study treatment was 8-weekly admin-
istration of canakinumab by s.c. injection, 150 mg to
adults and 2 mg/kg to patients ≤40 kg for up to 2 years.
Administration frequency and dose (maximum 600 mg
or 8 mg/kg [≤40 kg]) were increased in case of residual
symptoms.
Results
After insufficient response to per-protocol canakinu-
mab dose, the patient received high dose canakinu-
mab (10 mg/kg, i.v.) every 4 weeks from Day 20
onwards to >440 days. Disease activity improved
from severe to moderate at Day 48 and remained
stable including normal CRP and SAA values (<10
m g / L ) .T e m p o r a r ym i l da d v e r s ee v e n t s( A E )w e r en o t
suspected to be treatment-related (upper respiratory
viral infection, gastroenteritis, and rhinitis). Night
sweats, dry lips and skin persisted until last assess-
ments. No serious AEs /infections were reported in
this patient.
Conclusion
Based on our experience in this patient and a review of
literature on efficacy of IL-1 inhibition in CAPS patients
with V198M mutation, high dose canakinumab i.v* with
increased dosing frequency yields symptomatic relief
without evidence of increased AE. Confirmation of our
observation in more patients with similar genetic and
clinical presentation is needed.
*The posology used for this case is not in line with the
approved posology of canakinumab
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